I look forward to the NORD Rare Summit each year. It is a time to reflect on the work all of us do in the rare disease community−whatever area we work in, be it drug development, clinical research, regulatory compliance or patient advocacy. It’s a wonderful opportunity to collaborate as a community, truly learn from one another, and most importantly return to our work with a renewed focus and passion for advancing treatments for rare disease patients, knowing that the patient is central to all our work.
In a world of mounting cost pressures, providing effective patient services continues to be a key consideration for manufacturers of specialty medications. The right Hub design can optimize a manufacturer’s investment and lead to healthy (and happy) patients.
The 50th DIA Annual Meeting, which kicks off today, promises to be a blast. We’re looking forward to presenting some unique abstracts and connecting with industry colleagues at our social event. But the highlight of the event for our team is the chance to have fun while helping patients in a unique way.
Today kicks off the 23rd annual Partnerships in Clinical Trials (PCT) conference where we’re looking forward to connecting with many of our industry colleagues, having a little fun, and taking time to give back.
The theme of this year’s Rare Disease Day is “Join Together for Better Care.” UBC and Accredo employees live this mantra every day.
Less than one percent of the U.S. population uses specialty therapies, yet specialty drugs receive significant resources and development from pharma manufacturers. Last year marked the third consecutive year specialty drugs made up the majority of drugs approved by the FDA.
Small patient populations need big solutions. And, as exhibited by the table below featured in a recent FierceBiotech article, Express Scripts continues to show manufacturers that there is strength in size.
Pediatricians are known for saying that children aren’t just small adults; and their healthcare needs shouldn’t be treated that way. Giving children less of the same medicine or ordering a smaller MRI just doesn’t work.
Over the last two weeks, the Senate and the House passed their versions of the Food and Drug Administration Safety and Innovation Act. Conference committees will now work together to come up with a compromise, which could potentially be signed by President Obama this summer. The bill is nearly 400 pages long and covers such areas as user fees for novel, generic, and biosimilar medications, device regulation improvements, and drug shortage issues.
The World Orphan Drug Congress being held this week presents a unique opportunity for manufacturers, advocacy groups, and patient access providers to meet and discuss how we can all work together to take really good care of small, special patient populations.
One interesting discussion has been about whether small or large providers can best serve the needs of orphan drug manufacturers and their patients.